FKBP5 blockade may provide a new horizon for the treatment of stress-associated disorders; an in-silico study.
Ali Akbar Asadi-PooyaMahdi MalekpourBardia ZamiriMohammad KashkooliNegar FirouzabadiPublished in: Epilepsia open (2023)
While the current in-silico repurposing study could identify potential drugs (that are already approved and are widely available) for designing clinical trials in patients with stress-associated disorders (e.g., FS), any future clinical trial should consider the pharmacological profile of the desired drug and also the characteristics and comorbidities of the patients in order to foster a success.
Keyphrases
- clinical trial
- end stage renal disease
- chronic kidney disease
- emergency department
- molecular docking
- ejection fraction
- prognostic factors
- current status
- randomized controlled trial
- study protocol
- open label
- drug induced
- risk assessment
- patient reported outcomes
- combination therapy
- electronic health record
- stress induced
- peritoneal dialysis
- heat stress